Research Progress of Olverembatinib in the Treatment of Chronic Myeloid Leukemia
-
Published:2023
Issue:08
Volume:13
Page:12321-12325
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Subject
General Engineering
Reference22 articles.
1. Deininger, M.W., Shah, N.P., Altman, J.K., et al. (2020) Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 18, 1385-1415.
2. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
3. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
4. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
5. S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT